Summary
Becton, Dickinson and Company (BDX) reported revenues of $20.178 billion for the fiscal year ended September 29, 2024, representing a 4.2% increase year-over-year. This growth was driven by strong performance across its Medical, Life Sciences, and Interventional segments, notably boosted by the recent acquisition of Edwards Lifesciences' Critical Care product group. The company highlighted strategic objectives centered on growth, simplification, and empowerment, with a focus on innovation in smart devices, robotics, and AI. While facing some headwinds from market dynamics in China and inflationary pressures on labor and materials, BD demonstrated resilience with robust operating income and significant cash flow from continuing operations. The company continued to return value to shareholders through dividends and share repurchases. BD is actively managing various risks, including supply chain disruptions, regulatory scrutiny (particularly with its Alaris infusion pump business and a recent FDA warning letter for dispensing products), and cybersecurity threats. The company's proactive approach to risk management and commitment to innovation position it for continued development in the global medical technology market.
Financial Highlights
56 data points| Revenue | $20.18B |
| Cost of Revenue | $11.05B |
| Gross Profit | $9.13B |
| R&D Expenses | $1.19B |
| SG&A Expenses | $4.86B |
| Operating Expenses | $17.78B |
| Operating Income | $2.40B |
| Interest Expense | $528.00M |
| Net Income | $1.71B |
| EPS (Basic) | $5.88 |
| EPS (Diluted) | $5.86 |
| Shares Outstanding (Basic) | 289.76M |
| Shares Outstanding (Diluted) | 291.01M |
Key Highlights
- 1BDX reported fiscal year 2024 revenues of $20.178 billion, a 4.2% increase year-over-year, indicating continued top-line growth.
- 2The acquisition of Edwards Lifesciences’ Critical Care product group (now BD Advanced Patient Monitoring) for $3.911 billion in September 2024 significantly expanded BD's Medical segment capabilities, particularly in advanced patient monitoring.
- 3The company generated strong cash flow from continuing operations of $3.844 billion in fiscal year 2024, supporting its investment in R&D, strategic acquisitions, and returning value to shareholders via dividends and share repurchases.
- 4BD is focused on strategic objectives of 'Grow, Simplify, Empower,' emphasizing innovation in areas like smart devices, AI, and improving operational efficiencies.
- 5While revenue grew, the company highlighted challenges including market dynamics in China (like volume-based procurement), increased labor costs, and ongoing supply chain pressures.
- 6BD is managing significant regulatory matters, including a consent decree related to its Alaris infusion pumps and a recent FDA warning letter for its dispensing quality management system, which have associated costs and ongoing remediation efforts.
- 7The company reported a gross profit margin of 45.2% for FY2024, an improvement from 42.2% in FY2023, partly due to favorable purchase accounting adjustments and productivity initiatives.